AMIX - AMIX

Option chain shows key data for Autonomix Medical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Autonomix Medical.

Autonomix Medical (NASDAQ:AMIX) Stock, Option Chain

Autonomix Medical

Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.

Crollo del Nasdaq: gli insider si sbarazzano di questi titoli

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

AMIX

BORR

EVOK

HCTI

S&amp;P 500 Moves Higher; Philips Shares Plunge After Q3 Earnings

Intraday Update

Crude Oil Tumbles Over 5%; Autonomix Medical Shares Spike Higher

Cancer-Image by PDPics from Pixabay-

Health Care

Movers

General

Autonomix Medical stock surges on high volume as early trial results show pain reduction in pancreatic cancer patients, with some ceasing opioids.

Why Is Nao-Cap Neurology Focused Autonomix Medical Stock Trading Higher On Monday?

Autonomix Medical Inc

TELO

Telomir Pharmaceuticals Announced Preclinical Results Confirming The Efficacy Of Telomir-1, A Compound Designed To Effectively Turn Back The Biological Clock And Support Longevity

Contracts

Tech

UPBD

Upbound Has Announced An Agreement With Google Cloud To Deliver Advanced AI Solutions Designed To Significantly Improve The Experience For Customers, As Well As Expand Customer Offerings Across Upbound's Acima Leasing And Rent-A-Center Lines Of Business

SpaceX provided a conceptual image of the Starship Human Landing System (HLS) aimed at enabling astronauts to land back on the surface of the Moon for the first time since 1971.
What Happened: The HLS version of the Starship will not have a heat shield and flaps aimed at protecting the vehicle against the heat of Earth&#8217;s atmosphere. Instead, it will have landing legs aimed at enabling it to land on the Moon, SpaceX CEO Elon Musk said on Tuesday.
&#8220;This could (of course) only be used between trans-lunar orbit and lunar surface, given no heat shield or flaps,&#8221; he said in a post on X.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Starship will be used to land astronauts on the lunar surface on NASA&#39;s Artemis III mission, which will put the first humans on the Moon since 1972 <a href="https://t.co/qLiRp0PSAp">pic.twitter.com/qLiRp0PSAp</a>
&mdash; SpaceX (@SpaceX) <a href="https://twitter.com/SpaceX/status/1858991247312212112?ref_src=twsrc%5Etfw">November 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Starship HLS, which is about 50 meters tall, will carry astronauts from lunar orbit to the Moon&#8217;s surface and back for NASA&#8217;s Artemis 3 and 4 missions, <a href="https://www.benzinga.com/news/24/10/41400036/nasa-assigns-2-missions-to-spacex-for-2025-after-boeings-starliner-stranded-astronauts">according to NASA</a>.
Why It Matters: During the Artemis 3 mission, slated for no earlier than September 2026, the Starship HLS will be launched first and it will wait for NASA&#8217;s Orion spacecraft in lunar orbit after filling its tanks in space. Once the Orion spacecraft arrives, the HLS will dock with it. Two of the four crew members on the mission will transfer from Orion to Starship and descend to the surface of the moon.
On the completion of their mission objections on the surface of the moon in about a week, they will return in the Starship to the Orion spacecraft waiting in lunar orbit and subsequently return to Earth.
However, before attempting the crewed mission, SpaceX will also perform an uncrewed landing demonstration on the Moon.
The last time humans set foot on the Moon was in 1972&nbsp;<a href="https://www.benzinga.com/news/24/01/36692749/just-a-worse-version-of-apollo-elon-musk-baffled-by-nasa-veterans-push-to-ditch-spacex-blue-origin-a" target="_blank" rel="noreferrer noopener">with Apollo 17</a>. Since then, no crew has traveled beyond low-Earth orbit.
Starship is currently in the development and testing phase. The company has completed <a href="https://www.benzinga.com/general/space/24/11/42105704/spacex-ceo-elon-musk-reveals-technical-glitch-that-led-company-to-drop-key-objective-of-starships-6th-test-flight">6 flight tests</a> of the launch vehicle so far but it has yet to carry any payload to space. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42058338/byd-makes-a-million-nevs-in-less-than-2-months" target="_blank" rel="noreferrer noopener">BYD Makes A Million NEVs In Less Than 2 Months After Beating Tesla For The First Time Since 2022 In Quarterly Revenue</a></li>
</ul>
Photo courtesy: SpaceX

SPACE

SpaceX Shows Off Starship Concept Designed To Help Humans Land Back On Moon In Over 50 Years

This integration, which follows a successful beta phase, embeds&nbsp;WebCargo by Freightos air cargo eBooking into e2open's Transportation Management System (TMS) application.

CRGO

ETWO

Freightos Reports Official Launch Of Its Integration With e2open

Fearnleys analyst Fredrik Dybwad upgrades SFL Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFL#NYSE">SFL</a>) from Hold to Buy and announces $13 price target.

Upgrades

Price Target

Analyst Ratings

Fearnleys Upgrades SFL Corp to Buy, Announces $13 Price Target

William Blair analyst Andy Hsieh downgrades Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) from Outperform to Market Perform.

Downgrades

PYXS

William Blair Downgrades Pyxis Oncology to Market Perform

<a href="https://www.benzinga.com/real-estate/24/06/39534633/new-york-renters-may-benefit-from-huge-potential-change-in-rental-laws">Renters in New York City</a> may feel some relief as the City Council passed legislation eliminating tenant-paid broker fees. For decades, this practice has cost renters thousands of dollars in up-front moving costs.
The Fairness in Apartment Rentals (FARE) Act passed with a veto-proof majority of 42-8, shifting broker fee responsibility to landlords and management companies who hire the agents. The new law will take effect within 180 days of signing.
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>
Despite being <a href="https://www.benzinga.com/real-estate/24/05/39091231/rents-are-so-high-in-new-york-city-that-even-135kyear-tech-workers-cant-keep-up">one of the most expensive rental markets in the U.S.</a>, New York City tenants often pay broker fees up to 15% of their first year&#8217;s rent, even when they didn&#8217;t hire the broker. "New Yorkers have been getting ripped off for decades and decades," strategist Bradley Tusk, who pledged $10,000 to support the bill&#8217;s implementation, said in a statement originally reported by the Gothamist.
City Councilmember Chi Ossé introduced the bill and addressed concerns about landlords passing costs to tenants through higher rents. "Forty-seven percent of homes for tenants in New York City are rent-stabilized, so it would be illegal for landlords to bake the fee into rent in that case," Ossé told CBS News.
The real estate industry strongly opposes the change. "The FARE Act, while well-intentioned, is misguided," Ashley Murphy, senior vice president at Brown Harris Stevens, told Realtor.com. "If landlords are forced to pay broker fees, they will likely bake the price into the rent and the lease will be more expensive each and every time a tenant goes to renew."
Trending: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a>
The legislation requires landlords to disclose all tenant fees in rental listings and agreements. Violations carry penalties of up to $1,000 for first offenses and $2,000 for subsequent infractions within two years.
NYC Mayor Eric Adams expressed reservations about the bill&#8217;s impact. "The bill has the right intentions, but sometimes good intentions do not get the results you&#8217;re looking for," Adams said following the vote.
Beyond eliminating broker fees, the law mandates detailed fee disclosures signed by tenants before executing the lease. Landlords must retain the records for three years and provide copies to tenants.
The Department of Consumer and Worker Protection can pursue civil penalties and restitution in court, while individuals maintain the right to bring civil actions over violations.
Read Next:
<ul>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Real Estate

'New Yorkers Have Been Getting Ripped Off for Decades': NYC Council Ends Broker Fees For Tenants

Legal

HROW

Harrow's Subsidiary ImprimisRx Announced A Favorable Jury Verdict In The Case Vs. OSRX Alleging Willful Acts Of Trademark Infringement Against OSRX And Its Related Party, Ocular Science, The $34.9M Verdict Includes $20.4M In Punitive Damages And $14.5M In Actual Damages

CART

Instacart Announces New Supplemental Nutrition Access Program Eligibility Screener Available On EBT SNAP Information Page

The two-story building sits on 2.63 acres and was previously an Extra Space Storage business. It houses a variety of 975 indoor climate-controlled and heated self-storage rooms available for rent at affordable price points. Covered drive-in load/unload areas offer protection from the weather.

UHAL

U-Haul Buys Former Extra Space Storage Facility In Minneapolis; No Terms Disclosed

<ul>
<li>Muddy Waters' latest report is an attempt by a noted short seller to negatively impact e.l.f. Beauty's share price for its own benefit and at the expense of all other e.l.f. Beauty shareholders, and Muddy Waters' allegations are without merit. Muddy Waters has made numerous inaccurate statements about e.l.f. Beauty and our business by relying upon incomplete data and flawed assumptions, omitting critical context, and presenting speculation as fact.</li>
<li>In particular, in early 2024, for competitive reasons and as permitted by applicable regulations, we filed a request for confidentiality with U.S. Customs and Border Protection with respect to our customs import data. Therefore, import data available to the public after February 6, 2024, does not include a substantial majority of our actual U.S. imports.</li>
<li>Further, Muddy Waters' assertions do not align with the strong consumption data published by Nielsen and Circana.</li>
<li>We have rigorous inventory control procedures, including regular physical and cycle counts across our global distribution network. Similarly, we have rigorous controls and procedures around revenue recognition. We are fully confident in our financial statements.</li>
<li>Our recently announced second quarter fiscal 2025 financial results – marking our 23rd consecutive quarter of both net sales growth and market share gains – demonstrate our strong momentum and underscore our confidence in our business model and strategy. e.l.f. Beauty continues to deliver consistent, category leading growth.</li>
</ul>

Short Sellers

e.l.f. Beauty Issued A Statement In Response To A Report Published By Muddy Waters Research Saying  Allegations Are Without Merit; Company Is Fully Confident In Financial Statements

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Buy and raises the price target from $32 to $37.

KURA

HC Wainwright & Co. Maintains Buy on Kura Oncology, Raises Price Target to $37

Biotech

QURE

uniQure Has Dosed The First Patient In GenTLE Phase 1/2a Trial Of AMT-260 For Refractory Mesial Temporal Lobe Epilepsy

Kong-Picarello will join Terex on February 3, 2025 and assume her duties as Chief Financial Officer of Terex later in February shortly after Terex files its 2024 Annual Report on Form 10-K.&nbsp;
Beck will remain in her current role until Ms. Kong-Picarello assumes the duties of Chief Financial Officer. Beck will then continue with the Company until April 1 to assist with the transition.

Management

Terex Names Jennifer Kong-Picarello To Succeed Julie Beck As Senior Vice President And CFO

Arthur J. Gallagher Acquired Santiago, Chile-based THB Chile, Deal Terms Were Not Disclosed

UBS analyst Alex Kramm initiates coverage on Broadridge Financial Soln (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>) with a Neutral rating and announces Price Target of $250.

Initiation

UBS Initiates Coverage On Broadridge Financial Soln with Neutral Rating, Announces Price Target of $250

First Quarter and Full Year Fiscal 2025 Outlook
For the fiscal quarter ending December 31, 2024, revenue is expected to be in the range of $47 million to $50 million. GAAP net loss is expected to be in the range of ($26) million to ($23) million. Adjusted EBITDA is expected to be in the range of ($9) million to ($6) million.
For the full fiscal year ending September 30, 2025, the company expects revenue to be in the range of $236 million to $247 million which includes an estimated $20 million of fixed contracts at the mid-point of guidance. GAAP net loss is expected to be in the range of ($40) million to ($29) million. Adjusted EBITDA is expected to be in the range of $15 million to $26 million.

Guidance

CRNC

Cerence Expects Q1 Revenue Of $47M-$50M Vs $47.65M Est, FY25 Revenue Of $236M-$247M Vs $324.34M Est

Optune Gio is a wearable, portable device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing cancer cells, which disrupt the rapid cell division exhibited by cancer cells.
The new HFE arrays utilize a flexible polymer material in place of the ceramic discs used in the current Optune Gio arrays, making them one-third lighter and 50% thinner.

NVCR

The FDA Approves Novocure's New Head Flexible Electrode Transducer Arrays For Use With Optune Gio For Adult Patients With Glioblastoma Multiforme, Novocure Plans To Convert Optune Gio Users In The U.S. To The New HFE Arrays Through The First Half Of 2025 Through A Controlled Transition Plan

TRNR

Interactive Strength  Board Approves Maximum Cumulative Bitcoin Purchase Of Up To $5M;  Plans To Accept Payment In Digital Currencies

CATO

Cato Q3 EPS $(0.79) Down From $(0.30) YoY, Sales $144.6M Down From $156.7M YoY

19:50 EDT Autonomix (AMIX) Medical Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving br...

Autonomix Medical Inc trading halted, news pending

09:30 EDT Autonomix (AMIX) Medical Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, mark...

Autonomix Medical Inc trading halted, volatility trading pause

09:35 EDT Autonomix (AMIX) Medical Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financ...

Autonomix Medical Inc trading resumes

09:43 EDT Autonomix (AMIX) Medical Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financ...

09:38 EDT Autonomix (AMIX) Medical Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, mark...

Ladenburg Thalmann is acting as manager. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try ...

Autonomix files to sell 698,812 common stock units

14:46 EST Autonomix (AMIX) Medical Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financ...

14:36 EST Autonomix (AMIX) Medical Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, mark...

"Over the course of the past quarter we have made significant progress in our ongoing human clinical trial and generated a growing body of encourag...

Autonomix reports Q2 incurred net losses $2.8M vs $6M last year

Autonomix Medical reports Q2 results

Screenshot 2024-10-02 at 5.21.14 PM

This Company Is Taking An Innovative, Non-Opioid Approach To Pain Management For Pancreatic Cancer

Screenshot 2024-07-11 at 9.17.30 PM

Autonomix&#39;s Trial Results Show Meaningful Reduction In Pain For Patients Suffering From Pancreatic Cancer

Screenshot 2024-06-12 at 6.28.14 PM

Movers & Shakers

Discover How This Company&#39;s Breakthrough Technology Might Be The Key To Transforming Pancreatic Cancer Pain Relief

Screenshot 2024-06-05 at 7.12.02 PM

This One Company Is Working On A Breakthrough Approach To Revolutionize Pain Management

Screenshot 2024-05-07 at 11.14.55 PM

3000x More Sensitive Than What Is On The Market – This Technology Moves The Needle

Screenshot 2024-04-10 at 6.42.30 PM

Autonomix Medical (NASDAQ: AMIX) Is Cracking the Code Of The Peripheral Nervous System With Its Breakthrough Technology To Treat Diseases

The Nervous System Is Central To The Body, Yet Limited CNS Diagnostic Tools Exist – This Company Wants To Change That

Press Releases

Autonomix Selected to Present at the 2024 Octane Medical Innovation Forum

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

Autonomix Medical, Inc. to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC

Autonomix Announces Reverse Stock Split

Autonomix Medical, Inc. to Participate in a Virtual Investor "What This Means" Segment on Wednesday, October 30th

Positive Preliminary Results Demonstrate Autonomix's Proprietary RF Ablation Technology's Ability to Reduce Opioid Use in Ongoing Human Clinical Trial

Autonomix Medical, Inc.'s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial

Autonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients' 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction

Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

Comments

Autonomix Medical

Autonomix Medical (AMIX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga